Shares of Ionis Pharmaceuticals (IONS) surged 6.88% in pre-market trading on Wednesday following the company's release of better-than-expected first-quarter 2025 financial results and a significant increase in its full-year revenue guidance.

The biotechnology company reported Q1 revenue of $132 million, surpassing the average analyst estimate of $125.3 million. Ionis also posted an adjusted loss per share of $0.93, which was narrower than the expected loss of $1.10 per share. The company's performance was driven by higher commercial revenue, including new product sales from TRYNGOLZA and increased royalty revenues from SPINRAZA and WAINUA.

In a move that particularly excited investors, Ionis raised its 2025 financial guidance substantially. The company now expects full-year revenue between $725 million and $750 million, up more than 20% from its previous forecast of over $600 million. This optimistic outlook reflects recent successful licensing transactions and strong commercial execution. Additionally, Ionis reported encouraging progress in its product pipeline, including positive updates on its TRYNGOLZA launch for familial chylomicronemia syndrome and the anticipated launch of donidalorsen for hereditary angioedema later this year.